A phase Ib dose-escalation and expansion study of the BCL2 inhibitor venetoclax combined with tamoxifen in ER and BCL2-positive metastatic breast cancer
Open accessPublished version of a preprint
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Abstract Venetoclax, a potent and selective BCL2 inhibitor, synergizes with endocrine therapy in preclinical models of ER-positive breast cancer. Using a phase Ib 3 + 3 dose-escalation and expansion study design, 33 patients with ER and BCL2-positive metastatic disease (mean prior regimens, 2; range, 0–8) were treated with daily tamoxifen (20 mg) and venetoclax (200–800 mg). Apart from uncomplicated “on-target” lymphopenia, no dose-limiting toxicities or high-grade adverse events were observed in the escalation phase (15 patients), and 800 mg was selected as the recommended phase II dose (RP2D). In the expansion phase (18 patients), few high-grade treatment-related adverse events were observed. For 24 patients treated at the RP2D, the confirmed radiologic response rate was 54% and the clinical benefit rate was 75%. Treatment responses were preempted by metabolic responses (FDG-PET) at 4 weeks and correlated with serial changes in circulating tumor DNA. Radiologic responses (40%) and clinical benefit (70%) were observed in 10 patients with plasma-detected ESR1 mutations. Significance: In the first clinical study to evaluate venetoclax in a solid tumor, we demonstrate that combining venetoclax with endocrine therapy has a tolerable safety profile and elicits notable activity in ER and BCL2-positive metastatic breast cancer. These findings support further investigation of combination therapy for patients with BCL2-positive tumors. See related commentary by Drago et al., p. 323. This article is highlighted in the In This Issue feature, p. 305
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Of note, venetoclax limits several features of CLL-associated immunosuppression in patients, including CTL exhaustion and NK-cell dysfunction (de Weerdt et al., 2019) and does not reduce the number of peripheral T cells in patients with HR + BCL2 + metastatic breast cancer (Lok et al., 2019).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Lok et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“Upregulation of survival proteins has been implicated in tumor growth and reduced sensitivity to anti-cancer therapy (10,11).”
BackgroundHarris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2008.08.010 · Cited by 51,384 · cited 4×
“The study was supported by funds from a National Health and Medical Research Council (Australia) grant.”
MethodInfluentialMolecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261 · cited 1×
“Luminal breast tumors, characterized by estrogen receptor (ER) expression, account for approximately 70% of all breast cancers and are responsible for the majority of breast cancer deaths (1,2).”
BackgroundA Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277 · cited 1×
“It is a well-recognized prognostic factor that can be readily assessed by immunohistochemistry or in genomic assays such as Oncotype DX® and PAM50/Prosigna® (15-17).”
MethodSupervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721 · cited 1×
“It is a well-recognized prognostic factor that can be readily assessed by immunohistochemistry or in genomic assays such as Oncotype DX® and PAM50/Prosigna® (15-17).”
MethodAn inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416 · cited 2×
“In pre-clinical studies, endometrial thinning had been observed when tamoxifen was combined with ABT-737, a pre-clinical lead that targets both BCL-2 and BCL-XL (18,27).”
BackgroundABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058 · cited 2×
“Venetoclax (ABT-199/GDC-0199) is a potent and highly selective inhibitor of BCL-2 (20) (Supplementary Fig.”
BackgroundPalbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007 · cited 2×
“Tumor response can be further enhanced with adjunctive therapy that includes mTOR inhibitors (3), isoform-specific PI3K inhibitors (4) and cyclin dependent kinase (CDK) 4/6 inhibitors (5-7).”
BackgroundResultEverolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863 · cited 1×
“Tumor response can be further enhanced with adjunctive therapy that includes mTOR inhibitors (3), isoform-specific PI3K inhibitors (4) and cyclin dependent kinase (CDK) 4/6 inhibitors (5-7).”
BackgroundAnalysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Dawson, S.-J., Tsui, D. W. Y., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S.-F., Dunning, M. J., Gale, D., Forshew, T., Mahler-Araujo, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213261 · Cited by 2,207 · cited 1×
“These findings are consistent with emerging evidence on the utility of ctDNA in monitoring disease (30).”
ResultSelf-citation3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,900 · cited 5×
“Comparable doses in hematological models predicted efficacy for venetoclax in patients with CLL (20-22).”
BackgroundInfluentialMONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., Park, I. H., Trédan, O., Chen, S.-C., Manso, L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.6155 · Cited by 1,744 · cited 1×
“Tumor response can be further enhanced with adjunctive therapy that includes mTOR inhibitors (3), isoform-specific PI3K inhibitors (4) and cyclin dependent kinase (CDK) 4/6 inhibitors (5-7).”
BackgroundFinn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398 · cited 1×
“While CDK4/6 inhibitors elicit potent anti-proliferative effects, they do not induce tumor cell death (9).”
BackgroundCerto, M., Moore, V. D. G., Nishino, M., Wei, G., Korsmeyer, S., Armstrong, S. A., & Letai, A. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.027 · Cited by 1,288 · cited 1×
“We elected to combine venetoclax with tamoxifen based on our pre-clinical data, which raised the possibility that tamoxifen therapy could induce ‘mitochondrial priming’ through elevation of BCL-2 (18), thereby rendering tumor cells more susceptible to BH3 mimetic therapy (35).”
MethodOverall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810527 · Cited by 1,276 · cited 1×
“The latter have transformed the treatment landscape with significant improvement in overall response and progression free survival, as well as overall survival benefit for the subset of patients with endocrine responsive disease (8).”
BackgroundESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,248 · cited 1×
“These findings are consistent with responses observed with tamoxifen in vitro in ER + tumor cells expressing this LBD mutation (41,42).”
Result4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,171 · cited 2×
“We further evaluated response according to guidelines for endocrine resistant disease (26).”
MethodActivating ESR1 mutations in hormone-resistant metastatic breast cancer
Robinson, D. R., Wu, Y.-M., Vats, P., Su, F., Lonigro, R. J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2823 · Cited by 1,145 · cited 1×
“These findings are consistent with responses observed with tamoxifen in vitro in ER + tumor cells expressing this LBD mutation (41,42).”
ResultTumour lysis syndrome: new therapeutic strategies and classification
Cairo, M. S., & Bishop, M. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05094.x · Cited by 1,076
Mouridsen, H., Gershanovich, M., Sun, Y., Pérez-Carrión, R., Boni, C., Monnier, A., Apffelstaedt, J., Smith, R., Sleeboom, H. P., Jänicke, F., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2596 · Cited by 1,015 · cited 2×
“- 13 that venetoclax will similarly augment tumor responses in conjunction with other commonly used endocrine therapies such as aromatase inhibitors or fulvestrant (32-34,36,37).”
BackgroundResultThe Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Razavi, P., Chang, M. T., Xu, G., Bandlamudi, C., Ross, D. S., Vasan, N., Cai, Y., Bielski, C. M., Donoghue, M. T. A., Jonsson, P., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.008 · Cited by 996 · cited 1×
“ESR1 and MAP3K1 mutations were mutually exclusive, as recently reported (29).”
BackgroundNabholtz, J. M., Buzdar, A., Pollak, M., Harwin, W., Burton, G., Mangalik, A., Steinberg, M., Webster, A., & von Euler, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3758 · Cited by 992 · cited 2×
“- 13 that venetoclax will similarly augment tumor responses in conjunction with other commonly used endocrine therapies such as aromatase inhibitors or fulvestrant (32-34,36,37).”
BackgroundResultVenetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Seymour, J. F., Kipps, T. J., Eichhorst, B., Hillmen, P., D’Rozario, J., Assouline, S., Owen, C., Gerecitano, J., Robak, T., De la Serna, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713976 · Cited by 940
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Petrakova, K., Blackwell, K. L., Winer, E. P., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy155 · Cited by 876 · cited 1×
“Tumor response can be further enhanced with adjunctive therapy that includes mTOR inhibitors (3), isoform-specific PI3K inhibitors (4) and cyclin dependent kinase (CDK) 4/6 inhibitors (5-7).”
BackgroundBonneterre, J., Thürlimann, B., Robertson, J. F. R., Krzakowski, M., Mauriac, L., Koralewski, P., Vergote, I., Webster, A., Steinberg, M., & von Euler, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3748 · Cited by 842 · cited 1×
“Nevertheless, it is noteworthy that the ORR (54%) and CBR (75%) observed here for the 800 mg cohort, compares favorably to historical studies of patients treated with tamoxifen in first line relapse, where reported ORR ranged between 17-33% and CBR between 38-56% (31-34).”
ResultDiNardo, C. D., Pratz, K. W., Letai, A., Jonas, B. A., Wei, A. H., Thirman, M., Arellano, M., Frattini, M. G., Kantarjian, H., Popovic, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30010-x · Cited by 722 · cited 1×
“- 4 activity in several other types of hematological malignancies (23-25).”
BackgroundESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer
Jeselsohn, R., Buchwalter, G., De Angelis, C., Brown, M., & Schiff, R. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.117 · Cited by 704 · cited 1×
“Although mutations in the LBD have been reported to confer relative resistance to tamoxifen and fulvestrant (40), it is noteworthy that a tumor response or prolonged stable disease (accompanied by a significant reduction in mutant ESR1 ctDNA) was observed in 7 of 10 patients harboring ESR1 mutations, notably in those…”
BackgroundRobertson, J. F. R., Bondarenko, I. M., Trishkina, E., Dvorkin, M., Panasci, L., Manikhas, A., Shparyk, Y., Cardona-Huerta, S., Cheung, K.-L., Philco-Salas, M. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32389-3 · Cited by 582 · cited 1×
“- 13 that venetoclax will similarly augment tumor responses in conjunction with other commonly used endocrine therapies such as aromatase inhibitors or fulvestrant (32-34,36,37).”
BackgroundBalko, J. M., Giltnane, J. M., Wang, K., Schwarz, L. J., Young, C. D., Cook, R. S., Owens, P., Sanders, M. E., Kuba, M. G., Sánchez, V., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0286 · Cited by 482 · cited 1×
“Pertinently, MCL-1 appears to be amplified in a subset of triple negative tumors that fail to respond to neoadjuvant therapy (39).”
BackgroundIbrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
Tam, C. S., Anderson, M. A., Pott, C., Agarwal, R., Handunnetti, S., Hicks, R. J., Burbury, K., Turner, G., Di Iulio, J., Bressel, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1715519 · Cited by 433 · cited 1×
“- 4 activity in several other types of hematological malignancies (23-25).”
BackgroundHowell, A., Robertson, J. F. R., Abram, P., Lichinitser, M. R., Elledge, R., Bajetta, E., Watanabe, T., Morris, C., Webster, A., Dimery, I., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.112 · Cited by 421 · cited 1×
“- 13 that venetoclax will similarly augment tumor responses in conjunction with other commonly used endocrine therapies such as aromatase inhibitors or fulvestrant (32-34,36,37).”
BackgroundMetabolic Flare: Indicator of Hormone Responsiveness in Advanced Breast Cancer
Mortimer, J. E., Dehdashti, F., Siegel, B. A., Trinkaus, K., Katzenellenbogen, J. A., & Welch, M. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.11.2797 · Cited by 410 · cited 1×
“- 10 patient (01-021) would be consistent with a ‘flare’ response (28), since a partial response by RECIST was observed at 12 weeks and metabolic activity was reduced at 16 weeks (not shown).”
BackgroundPerillo, B., Sasso, A., Abbondanza, C., & Palumbo, G. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.8.2890-2901.2000 · Cited by 333 · cited 1×
“BCL-2, a key member of the BCL-2 pro-survival family, is an estrogen responsive gene (12) and is overexpressed in approximately 80% of primary ER-positive (ER + ) breast cancers (13,14).”
BackgroundParidaens, R. J., Dirix, L. Y., Beex, L. V., Nooij, M., Cameron, D. A., Cufer, T., Piccart, M. J., Bogaerts, J., & Therasse, P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4659 · Cited by 319 · cited 2×
“- 13 that venetoclax will similarly augment tumor responses in conjunction with other commonly used endocrine therapies such as aromatase inhibitors or fulvestrant (32-34,36,37).”
BackgroundResultDawson, S.-J., Makretsov, N., Blows, F. M., Driver, K. E., Provenzano, E., Le Quesne, J., Baglietto, L., Severi, G., Giles, G. G., McLean, C. A., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605736 · Cited by 317 · cited 2×
“It is a well-recognized prognostic factor that can be readily assessed by immunohistochemistry or in genomic assays such as Oncotype DX® and PAM50/Prosigna® (15-17).”
BackgroundMethodInfluentialTargeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer
Vaillant, F., Merino, D., Lee, L., Breslin, K., Pal, B., Ritchie, M. E., Smyth, G. K., Christie, M., Phillipson, L. J., Burns, C. J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.06.002 · Cited by 276 · cited 6×
“BCL-2, however, is often expressed at high levels in poorer prognosis Luminal B tumors, as well as good prognosis Luminal A tumors (18).”
BackgroundMethodInfluentialSensitization of BCL-2–expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737
Oakes, S. R., Vaillant, F., Lim, E., Lee, L., Breslin, K., Feleppa, F., Deb, S., Ritchie, M. E., Takano, E., Ward, T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104778108 · Cited by 193 · cited 1×
“BCL-2, a key member of the BCL-2 pro-survival family, is an estrogen responsive gene (12) and is overexpressed in approximately 80% of primary ER-positive (ER + ) breast cancers (13,14).”
BackgroundMerino, D., Whittle, J. R., Vaillant, F., Serrano, A., Gong, J.-N., Giner, G., Maragno, A. L., Chanrion, M., Schneider, E., Pal, B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aam7049 · Cited by 185 · cited 1×
“Such functional redundancy among pre-survival BCL-2 family members seems plausible, given that they are commonly co-expressed in ER + tumors (18,38).”
BackgroundTargeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer
Merino, D., Lok, S. W., Visvader, J. E., & Lindeman, G. J. (2016) · Oncogene · doi:10.1038/onc.2015.287 · Cited by 161 · cited 1×
“BCL-2, a key member of the BCL-2 pro-survival family, is an estrogen responsive gene (12) and is overexpressed in approximately 80% of primary ER-positive (ER + ) breast cancers (13,14).”
BackgroundTargeting BCL-2-like Proteins to Kill Cancer Cells
Cory, S., Roberts, A. W., Colman, P. M., & Adams, J. M. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.07.001 · Cited by 161 · cited 2×
“These compounds mimic the natural antagonists of BCL-2 and related proteins (11,19).”
BackgroundLeverson, J. D., Sampath, D., Souers, A. J., Rosenberg, S. H., Fairbrother, W. J., Amiot, M., Konopleva, M., & Letai, A. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0797 · Cited by 128 · cited 1×
“These compounds mimic the natural antagonists of BCL-2 and related proteins (11,19).”
BackgroundPolyák, K., & Metzger, O. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.021 · Cited by 104
André, F., Ciruelos, E. M., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy424.010 · Cited by 67 · cited 1×
“Tumor response can be further enhanced with adjunctive therapy that includes mTOR inhibitors (3), isoform-specific PI3K inhibitors (4) and cyclin dependent kinase (CDK) 4/6 inhibitors (5-7).”
BackgroundJehanno, N., Giraudet, A., Champion, L., Lerebours, F., Stanc, E. L., Edeline, V., Madar, O., Bellet, D. H., Pecking, A. P., & Alberini, J. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1981-z · Cited by 62 · cited 1×
“A pilot study suggested that partial metabolic response to FDG-PET at ~10 weeks was predictive of improved progression free survival (43).”
Background
Research works printed but not linked: 1
- Seymour, 2013, Bcl-2 inhibitor ABT-199 (GDC-0199) monotherapy show anti-tumor activity including complete remissions in high-risk relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (abstract 7018), Blood, 122, 429s
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Small molecules, big impact: 20 years of targeted therapy in oncology
Bedard, P. L., Hyman, D. M., Davids, M. S., & Siu, L. L. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30164-1 · Cited by 610
Brett, J. O., Spring, L. M., Bardia, A., & Wander, S. A. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01462-3 · Cited by 414
“Lok SW, et al. A Phase Ib dose-escalation and expansion study of the BCL2 inhibitor venetoclax combined with tamoxifen in ER and BCL2positive metastatic breast cancer.”
BackgroundMitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy
Yamazaki, T., Kirchmair, A., Sato, A., Buqué, A., Rybstein, M., Petroni, G., Bloy, N., Finotello, F., Stafford, L., Navarro Manzano, E., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0751-0 · Cited by 359
The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs
Diepstraten, S. T., Anderson, M. A., Czabotar, P. E., Lessene, G., Strasser, A., & Kelly, G. L. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00407-4 · Cited by 346
Metadata
- Authors
- Lok, S. W., Whittle, J. R., Vaillant, F., Teh, C. E., Lo, L. L., Policheni, A. N., Bergin, A. R. T., Desai, J., Ftouni, S., Gandolfo, L. C., Liew, D., Liu, H. K., Mann, G. B., Moodie, K., Murugasu, A., Pal, B., Roberts, A. W., Rosenthal, M. A., Shackleton, K., Silva, M. J., Siow, Z. R., Smyth, G. K., Taylor, L., Travers, A., Yeo, B., Yeung, M. M., Bujak, A. Z., Dawson, S.-J., Gray, D. H. D., Visvader, J. E., & Lindeman, G. J.
- Affiliations
- The Royal Melbourne Hospital (AU)
- The University of Melbourne (AU)
- Peter MacCallum Cancer Centre (AU)
- Walter and Eliza Hall Institute of Medical Research (AU)
- Austin Health (AU)
- Corresponding author
- Lindeman, Geoffrey J.
- ORCID
- Lok, Sheau W.
- Whittle, James R.
- Vaillant, François
- Teh, Charis E.
- Lo, Louisa L.
- Policheni, Antonia N.
- Bergin, Alice R.T.
- Desai, Jayesh
- Ftouni, Sarah
- Gandolfo, Luke C.
- Liew, Danny
- Mann, G. Bruce
- Moodie, Kate
- Pal, Bhupinder
- Roberts, Andrew W.
- Rosenthal, Mark A.
- Silva, Maria João
- Smyth, Gordon K.
- Travers, Avraham
- Yeo, Belinda
- Yeung, Miriam M.
- Bujak, Andjelija Zivanovic
- Dawson, Sarah-Jane
- Gray, Daniel H.D.
- Visvader, Jane E.
- Lindeman, Geoffrey J.
- Venue
- Cancer Discovery
- Published
- 2019-03-01
- Volume
- 9
- Issue
- 3
- Pages
- 354-369
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2902257786
- Cited by
- 148
- References
- 45
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 17 · 2023: 21 · 2022: 21 · 2021: 33 · 2020: 22 · 2019: 11
- FWCI
- 15.97
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Monash University Research Portal (Monash University) (submittedVersion, other-oa)
- Funders
- National Health and Medical Research Council (1016701, 1040978, 1054618, 1078763, 1113133)
- Victorian Cancer Agency (TRP13041, 13-035)
- National Breast Cancer Foundation (NT-13-06)
- NHMRC (1089072, 1090236, 1100807, 1058892, 1037230, 1078730)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- venetoclax, tamoxifen, BCL-2 inhibitor, endocrine therapy, estrogen receptor-positive breast cancer, combination therapy, dose-limiting toxicity, circulating tumor DNA, ESR1 mutations, lymphopenia
- MeSH terms
- Circulating Tumor DNA, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Middle Aged, Neoplasm Metastasis, Sulfonamides, Tamoxifen, Tissue Distribution, Disease-Free Survival, Bridged Bicyclo Compounds, Heterocyclic, Proto-Oncogene Proteins c-bcl-2, Estrogen Receptor alpha
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.